Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01170234 · ClinicalTrials.gov registry record
Exhaled Nitric Oxide as a Biomarker of Disease Activity in Eosinophilic Esophagitis
A clinical trial, sponsored by Tufts Medical Center.
- Completed
- Registry status
- 14
- Enrollment target
NCT01170234 is a clinical trial that has completed, run by Tufts Medical Center. The registered enrollment target is 14 participants.
The verdict
NCT01170234 has completed, sponsored by Tufts Medical Center.
- COMPLETED
- Registry status
- 14 participants
- Enrollment target
Study Summary
There is currently no reliable, noninvasive biomarker for eosinophilic esophagitis (EoE), a chronic allergic diseases characterized by significant infiltration of eosinophils in the esophagus. Because eosinophils release nitric oxide, levels of exhaled nitric oxide (FeNO) are used routinely for guiding treatment in subsets of patients with asthma. FeNO levels are also elevated in immunological diseases that do not involve the airways. The investigators hypothesize that patients with EoE have elevated nitric oxide concentration in their exhaled breath and that changes in FeNO levels could be used to measure disease activity. The objective of this study is to determine the feasibility of using FeNO as a noninvasive surrogate marker for EoE disease activity. The investigators propose to measure serial exhaled nitric oxide (FeNO) levels on a group of patients with confirmed EoE, before, during and after the course of topical corticosteroid therapy to determine whether the level declines from pre-treatment level in individual patients.
Interventions
- DEVICE NIOX MINO® Airway Inflammation Monitor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2010-08 |
| Est. Completion | 2012-02 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01170234
The ClinicalTrials.gov registry entry for NCT01170234 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Tufts Medical Center, which has 169 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which NIOX MINO® Airway Inflammation Monitor is the first listed.
NCT01170234 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01170234 about?
NCT01170234 is a clinical study titled "Exhaled Nitric Oxide as a Biomarker of Disease Activity in Eosinophilic Esophagitis". There is currently no reliable, noninvasive biomarker for eosinophilic esophagitis (EoE), a chronic allergic diseases characterized by significant infiltration of eosinophils in the esophagus. Because eosinophils release nitric oxide, levels of exhaled nitric oxide (FeNO) are used routinely for guid...
What is the current status of trial NCT01170234?
This trial is currently completed. The enrollment target is 14 participants. The study started on 2010-08. Estimated completion is 2012-02.
What interventions are being tested in trial NCT01170234?
The interventions under investigation include: NIOX MINO® Airway Inflammation Monitor (DEVICE).
Who is sponsoring clinical trial NCT01170234?
This trial is sponsored by Tufts Medical Center, which has 169 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.